Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model
Open Access
- 9 July 2024
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (7) , e0011224
Abstract
Inhalation anthrax is the most severe form of Bacillus anthracis infection, often progressing to fatal conditions if left untreated. While recommended antibiotics can effectively treat anthrax when promptly administered, strains engineered for antibiotic resistance could render these drugs ineffective. Telavancin, a semisynthetic lipoglycopeptide antibiotic, was evaluated in this study as a novel therapeutic against anthrax disease. Specifically, the aims were to (i) assess in vitro potency of telavancin against 17 B. anthracis isolates by minimum inhibitory concentration (MIC) testing and (ii) evaluate protective efficacy in rabbits infected with a lethal dose of aerosolized anthrax spores and treated with human-equivalent intravenous telavancin doses (30 mg/kg every 12 hours) for 5 days post-antigen detection versus a humanized dose of levofloxacin and vehicle control. Blood samples were collected at various times post-infection to assess the level of bacteremia and antibody production, and tissues were collected to determine bacterial load. The animals’ body temperatures were also recorded. Telavancin demonstrated potent bactericidal activity against all strains tested (MICs 0.06–0.125 μg/mL). Further, telavancin conveyed 100% survival in this model and cleared B. anthracis from the bloodstream and organ tissues more effectively than a humanized dose of levofloxacin. Collectively, the low MICs against all strains tested and rapid bactericidal in vivo activity demonstrate that telavancin has the potential to be an effective alternative for the treatment or prophylaxis of anthrax infection.Keywords
Funding Information
- HHS | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201700040I/75N93019F00271)
This publication has 46 references indexed in Scilit:
- Responding to the Threat Posed by Anthrax: Updated Evidence to Improve PreparednessClinical Infectious Diseases, 2022
- Systematic Review of Hospital Treatment Outcomes for Naturally Acquired and Bioterrorism-Related Anthrax, 1880–2018Clinical Infectious Diseases, 2022
- Antimicrobial Activity of Telavancin Tested In Vitro Against a Global Collection of Gram-Positive Pathogens, Including Multidrug-Resistant Isolates (2015–2017)Microbial Drug Resistance, 2020
- Telavancin: Mechanisms of Action, In Vitro Activity, and Mechanisms of ResistanceClinical Infectious Diseases, 2015
- Key aspects of the molecular and cellular basis of inhalational anthraxMicrobes and Infection, 2011
- Telavancin: in vitro activity against staphylococci in a biofilm modelJournal of Antimicrobial Chemotherapy, 2005
- Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteriaJournal of Antimicrobial Chemotherapy, 2004
- Semi-synthetic glycopeptide antibacterialsBioorganic & Medicinal Chemistry Letters, 2003
- The pathogenesis of anthrax following the administration of spores by the respiratory routeThe Journal of Pathology and Bacteriology, 1957
- Observations on the prophylaxis of experimental pulmonary anthrax in the monkeyEpidemiology and Infection, 1956